SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-19-019770
Filing Date
2019-01-29
Accepted
2019-01-29 08:16:34
Documents
3
Period of Report
2019-01-24
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d697013d8k.htm 8-K 26253
2 EX-2.1 d697013dex21.htm EX-2.1 571130
3 EX-99.1 d697013dex991.htm EX-99.1 14484
  Complete submission text file 0001193125-19-019770.txt   613361
Mailing Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421
Business Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421 781-761-4904
Aldeyra Therapeutics, Inc. (Filer) CIK: 0001341235 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36332 | Film No.: 19547157
SIC: 2834 Pharmaceutical Preparations